Showing results (521-530 of 650) with videos related to
Sort By:
Pageof 65
Nature Cancer|February 5, 2022
Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasisMinhong Shen, Yong Wei, Hahn Kim, et al.Nature Cancer|February 5, 2022
Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancerMinhong Shen, Heath A Smith, Yong Wei, et al.Nature Cancer|February 5, 2022
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1Tong Zhang, Linchong Sun, Yijie Hao, et al.Nature Cancer|February 5, 2022
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemiaLu Wang, Noah Warren Birch, Zibo Zhao, et al.Nature Cancer|February 5, 2022
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapseFan Yang, Samuel W Brady, Chao Tang, et al.Nature Cancer|February 5, 2022
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcomeGil Friedman, Oshrat Levi-Galibov, Eyal David, et al.Nature Cancer|February 5, 2022
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trialAparna R Parikh, Annamaria Szabolcs, Jill N Allen, et al.Nature Cancer|February 5, 2022
NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiationFederico Mauri, Corentin Schepkens, Gaëlle Lapouge, et al.Nature Cancer|July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signalingBirgit Wilding, Dirk Scharn, Dietrich Böse, et al.Nature Cancer|July 14, 2022
Starfish infers signatures of complex genomic rearrangements across human cancersLisui Bao, Xiaoming Zhong, Yang Yang, et al.Pageof 65